Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 34Gynecologic 3Genitourinary 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 5Small Cell Lung Carcinoma 3Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Lung Diseases 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 48Nivolumab 22Cyclophosphamide 10Carboplatin 10spartalizumab 8atezolizumab 7Gemcitabine 7130-nm albumin-bound paclitaxel 7fludarabine 6Cisplatin 6Ipilimumab 5durvalumab 4budigalimab 4avelumab 4Pemetrexed 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Irinotecan 4Interleukin-2 4Immune Checkpoint Inhibitors 4Docetaxel 4Bevacizumab 4cemiplimab 3cabozantinib 3aldesleukin 3Standard of Care 3Specimen Handling 3Oxaliplatin 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × sacituzumab govitecan × Thoracic × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡